ProMIS Neurosciences to Participate in 7th Annual Evercore HealthCONx Conference
ProMIS Neurosciences to Participate in 7th Annual Evercore HealthCONx Conference
ProMIS Neurosciences Inc. is a clinical stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). The Company's proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. PMN310, the Company's lead product candidate for the treatment of AD, is a differentiated, humanized monoclonal antibody that has been designed to specifically bind toxic Aβ oligomers and to not bind plaque or monomers. Oligomers are known to drive disease progression in AD and PMN310 appears to be the only antibody to selectively bind oligomers, which is expected to support better safety and efficacy. PMN 310 has successfully completed a Phase 1a clinical study and ProMIS expects to initiate a Phase 1b clinical trial in AD patients by year end 2024. ProMIS has offices in Cambridge, Massachusetts and Toronto, Ontario.CAMBRIDGE, Massachusetts and TORONTO, Ontario, Nov. 26, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, will participate in a fireside chat at the 7th Annual Evercore HealthCONx Conference on Tuesday, December 3, 2024 at 1:20 p.m. ET in Coral Gables, FL.
馬薩諸塞州劍橋和安大略多倫多，2024年11月26日(GLOBE NEWSWIRE) -- 生物技術公司ProMIS Neurosciences Inc. (納斯達克: PMN)，專注於針對神經退行性疾病如阿爾茨海默病(AD)、肌萎縮性側索硬化症(ALS)和多系統萎縮(MSA)等疾病生成和開發抗體治療藥物的臨床階段公司，今日宣佈ProMIS Neurosciences首席執行官Neil Warma將於2024年12月3日星期二美東時間下午1:20在佛羅里達州Coral Gables參加第七次年度Evercore HealthCONx大會的爐邊聊天。
A live webcast of the fireside chat may be accessed by visiting the Events page of the Company's website at , and will be available for at least 30 days following the event.
可通過訪問該公司網站的事件頁面獲取爐邊聊天的現場網絡直播，網址爲 ，並將在活動結束後至少30天內提供。
About ProMIS Neurosciences Inc.
關於ProMIS Neurosciences Inc.
ProMIS Neurosciences Inc. is a clinical stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). The Company's proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. PMN310, the Company's lead product candidate for the treatment of AD, is a differentiated, humanized monoclonal antibody that has been designed to specifically bind toxic Aβ oligomers and to not bind plaque or monomers. Oligomers are known to drive disease progression in AD and PMN310 appears to be the only antibody to selectively bind oligomers, which is expected to support better safety and efficacy. PMN 310 has successfully completed a Phase 1a clinical study and ProMIS expects to initiate a Phase 1b clinical trial in AD patients by year end 2024. ProMIS has offices in Cambridge, Massachusetts and Toronto, Ontario.
ProMIS Neurosciences Inc.是一家專注於生成和開發選擇性靶向神經退行性疾病如阿爾茨海默病(AD)、肌萎縮性側索硬化症(ALS)和多系統萎縮(MSA)中有毒錯誤摺疊蛋白的抗體治療的臨床階段生物技術公司。該公司的專有目標發現引擎應用熱力學、計算發現平台——ProMIS和Collective Coordinates——以預測被稱爲特異疾病表位的新穎靶標，該表位位於錯誤摺疊蛋白的分子表面。作爲AD治療的首選藥物PMN310是一種不同凡響的人源化單克隆抗體，專門設計用於特異結合有毒的Aβ寡聚體且不與斑塊或單體結合。寡聚體被認爲驅動AD的疾病進展，PMN310似乎是唯一選擇性結合寡聚體的抗體，這有望支持更好的安全性和療效。PMN310已成功完成了一項1a期臨床研究，ProMIS預計將於2024年年底啓動針對AD患者的10億期臨床試驗。ProMIS在馬薩諸塞州劍橋和安大略多倫多設有辦公室。
For further information:
進一步了解：
Visit us at .
請訪問我們的網址.
Please submit media inquiries to info@promisneurosciences.com.
請將媒體諮詢提交至 info@promisneurosciences.com.
For Investor Relations, please contact:
如需投資者關係，請聯繫：
Precision AQ (formerly Stern IR)
Anne Marie Fields, Managing Director
annemarie.fields@precisionaq.com
Tel. 212-362-1200
Precision AQ（前稱Stern IR）
Anne Marie Fields，董事總經理
annemarie.fields@precisionaq.com
電話：212-362-1200
